Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBATER: Abciximab and Stents in STEMI
NCT00986050Phase 4Completed
- Sponsor
- Catharina Ziekenhuis
- Start
- Jan 2006
- Primary completion
- May 2008
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abciximab in ST-segment elevation myocardial infarction (STEMI) (4 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Target Vessel Failure at 1 year. Started Jan 2006; status: completed.
02
Drugs
abciximab
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00986050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986050.